Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

by Business Wire • 2025/02/04 • 0 Comments

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. The conference is being conducted virtually on February 11, 2025. Dr. Brady’s co

← VIDEO: EVO ICL a reliable option for low to moderate myopia

McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC →

Post navigation